Clinical Trial News and Research

RSS

Brief exposure to general anesthesia during infancy does not affect neurological development

Although the medical community has raised concerns about the safety of anesthesia on the developing brains of young children, new research presented at the ANESTHESIOLOGY 2015 annual meeting, found brief exposure to general anesthesia during infancy did not impair neurological development. This is the first prospective, randomized, controlled clinical trial to assess the long-term, neurological effects of anesthesia in children.

27 Oct 2015

New study identifies molecular mechanism that prevents immunotherapy drugs from killing off cancer

Immunotherapy treatments have proven wildly successful in treating some patients with cancer. But despite this success, the majority of patients do not respond to the treatments.

27 Oct 2015

New drug combination may be effective against malignant melanoma

A team of Massachusetts General Hospital investigators has discovered a new combination of drugs that may be effective against one of the deadliest cancers, malignant melanoma. The combination - pairing a drug targeted against mutations in the BRAF gene with a second drug that targets another important signaling pathway - was discovered through one of the largest screens of cancer drug combinations conducted to date.

27 Oct 2015

Patients with treatment-resistant autoimmune blood conditions may benefit from sirolimus

The immunosuppressant sirolimus is an effective and safe steroid-sparing therapy for children and young adults with highly treatment-resistant autoimmune blood conditions, according to a study published online today in Blood, the Journal of the American Society of Hematology.

27 Oct 2015

Advanced pancreatic cancer patients now have access to new FDA-approved drug, Onivyde

Patients with advanced pancreatic cancer now have access to the new FDA approved drug, Onivyde, that produced significant overall survival rates in an international clinical study conducted in part by researchers at HonorHealth Research Institute and the Translational Genomics Research Institute.

27 Oct 2015

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure, and stroke, announced that it has initiated its Phase 2 study of vepoloxamer for the treatment of patients with chronic heart failure.

26 Oct 2015

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that one of its subsidiaries, Sinovac Dalian, has received approval to begin human clinical trials on its varicella vaccine candidate. The clinical trial application for the varicella vaccine was officially accepted by the China Food and Drug Administration in January 2013.

26 Oct 2015

New approaches to treating lung cancer patients in New Mexico

This year, more than 158,000 Americans are expected to die from lung cancer. That's a staggering number: it's more than all the deaths expected from breast, prostate, colon, rectum, bladder and skin cancers combined.

26 Oct 2015

NYSCF conference to focus on translational stem cell and neuroscience research

The New York Stem Cell Foundation 10th Annual Translational Stem Cell Research Conference convenes global leaders in translational stem cell and neuroscience research to present their latest work towards new treatments and cures for the most devastating diseases and injuries currently facing the world.

26 Oct 2015

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

The U.S. Food and Drug Administration today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic).

24 Oct 2015

Strensiq approved for treatment of patients with juvenile-onset HPP

Today, the U.S. Food and Drug Administration approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).

24 Oct 2015

Minimally invasive implant procedure effective for patients with sacroiliac joint dysfunction

A minimally invasive implant procedure is highly effective in reducing pain and disability for patients with sacroiliac joint (SIJ) dysfunction, reports a clinical trial in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons, published by Wolters Kluwer.

23 Oct 2015

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year.

23 Oct 2015

Medlab granted ethics approval to begin human trials using nanotechnology delivery platform

Sydney-based, ASX listed, biopharmaceutical company, Medlab Clinical Ltd has been granted ethics approval to progress to two separate human trials using its nanotechnology delivery platform.

23 Oct 2015

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Eli Lilly and Company today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors.

22 Oct 2015

Major UK trial to examine role of aspirin in cancer recurrence

The world's largest ever clinical trial looking at whether taking aspirin every day stops some of the most common cancers coming back, launches across the UK today (Thursday).

22 Oct 2015

NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

NHS Blood and Transplant will start producing stem cells for groundbreaking treatment aimed at combating one of the most serious health problems facing the NHS, diabetic kidney disease.

22 Oct 2015

Melatonin and the circadian rhythm: an interview with Professor Kennaway, University of Adelaide

The production of melatonin is controlled by a part of the brain called the suprachiasmatic nucleus (SCN) and its timing fine-tuned by our exposure to light during the morning.

20 Oct 2015

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee has reviewed the initial safety data from all three patients in the first cohort and has recommended dose escalation to the second cohort.

20 Oct 2015

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

In the UK there are currently over 3.5 million people who have diabetes, with a growth rate exceeding 280,000 people per year. Diabetic retinopathy is the most common complication of diabetes.

19 Oct 2015

Clinical Trial News and Research

Brief exposure to general anesthesia during infancy does not affect neurological development

New study identifies molecular mechanism that prevents immunotherapy drugs from killing off cancer

New drug combination may be effective against malignant melanoma

Patients with treatment-resistant autoimmune blood conditions may benefit from sirolimus

Advanced pancreatic cancer patients now have access to new FDA-approved drug, Onivyde

Mast Therapeutics begins vepoloxamer Phase 2 study in patients with chronic heart failure

Sinovac Dalian receives approval to start human clinical trials of varicella vaccine candidate

New approaches to treating lung cancer patients in New Mexico

NYSCF conference to focus on translational stem cell and neuroscience research

FDA approves Yondelis (trabectedin) for treatment of specific soft tissue sarcomas

Strensiq approved for treatment of patients with juvenile-onset HPP

Minimally invasive implant procedure effective for patients with sacroiliac joint dysfunction

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

Medlab granted ethics approval to begin human trials using nanotechnology delivery platform

Lilly expands existing immuno-oncology collaboration with AstraZeneca

Major UK trial to examine role of aspirin in cancer recurrence

NHS to produce unique stem cells that could revolutionize treatment for diabetic kidney disease

Melatonin and the circadian rhythm: an interview with Professor Kennaway, University of Adelaide

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Diabetic retinopathy therapy innovations: an interview with Richard Kirk, CEO of Polyphotonix

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer